Heavy repeated unsupervised psilocybin use followed by psychosis with catatonic features in a predisposed adult male

Source note

Anonymised summary of Morris (2024), Clinical Psychopharmacology and Neuroscience. Clinic location and personal identifiers are omitted.

Participant profile (non-identifying)

• Age / sex: 37-year-old male
• Background vulnerabilities noted by the author: history of depression; personality-disorder traits (schizoid/avoidant described as premorbid); chronic cannabis use; possible masked prodromal or bipolar vulnerability

Exposure pattern

Several months of heavy / repeated psilocybin use outside a research protocol (exact milligram totals not fully quantified in the public case narrative).

Clinical course (as published)

Development of a psychotic episode with catatonic features and suicidality, alongside depressive symptoms — requiring clinical care. The author situates the case within a broader literature pattern: psilocybin-associated psychosis clusters in people with predisposing factors after high or repeated dosing.

Why this anecdote is included

This is a harm signal, not a treatment success story. It supports PSILORIS’s negative status for psychotic disorders / high psychosis risk and the standard trial practice of excluding psychosis vulnerability.